NCT07419295 2026-02-19
TroFuse-031
Merck Sharp & Dohme LLC
Phase 3 Not yet recruiting
Clinical Trials
12 trialsNCT03661320 2026-02-03
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT03556904 2026-01-15
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT02454543 2026-01-12
g-RAMPP
Martini-Klinik am UKE GmbH
Phase NA Active not recruiting
NCT06120374 2025-12-30
Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC
Peking University First Hospital
Recruiting
NCT07261592 2025-12-03
Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 1/2 Not yet recruiting
NCT07163910 2025-11-18
Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical Study
Zhongda Hospital
Phase 2 Recruiting
NCT06727214 2025-09-30
AssiutU
Assiut University
Not yet recruiting
NCT05704985 2025-05-29
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
Phase 1 Active not recruiting
NCT02649829 2025-04-29
MESODEC
University Hospital, Antwerp
Phase 1/2 Completed
NCT06196736 2025-04-13
A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 3 Recruiting
NCT00938145 2025-04-11
3 Tesla MRI in Patients With Bladder Cancer
University of Cincinnati
Phase NA Active not recruiting